Buscopan for Biliary Colic
Buscopan (hyoscine butylbromide) can be used for biliary colic but is significantly inferior to NSAIDs like diclofenac, which should be the first-line treatment for both pain relief and prevention of progression to acute cholecystitis.
Primary Recommendation
NSAIDs (specifically diclofenac 75 mg IM) are superior to hyoscine butylbromide for biliary colic. In a head-to-head trial, diclofenac provided faster and more complete pain relief (91.7% vs 69.4% pain-free at 4 hours, p=0.037) and, most importantly, prevented progression to acute cholecystitis in significantly more patients (16.7% vs 52.8% progression rate, p=0.003) 1. This mortality and morbidity benefit makes NSAIDs the clear first choice.
When Buscopan May Be Appropriate
Hyoscine butylbromide has a role as:
- Second-line therapy when NSAIDs are contraindicated (active GI bleeding, severe renal impairment, NSAID allergy)
- Intraoperative adjunct during cholecystectomy when choledocholithiasis is incidentally discovered on intraoperative cholangiogram, where it achieved 55.2% success rate for stone passage 2
Dosing and Administration
Standard dose: 20 mg IV/IM for acute biliary colic 3, 1
- Onset of action: within 10 minutes
- Pain reduction observed: 42-78% within 30 minutes 3
- Can repeat dosing, though single injection is typical for acute episodes
For oral maintenance (functional biliary disorders): 20 mg 5 times daily 4
Mechanism and Efficacy Profile
Hyoscine butylbromide is a quaternary ammonium anticholinergic that:
- Blocks muscarinic (primarily M3) receptors on GI smooth muscle 5
- Does NOT cross the blood-brain barrier (no CNS side effects) 3, 6
- Has <1% systemic bioavailability when given orally but maintains local GI effect 6
- Provides spasmolytic effect by relaxing biliary smooth muscle
Critical Contraindications
Absolute contraindications:
- Narrow-angle glaucoma
- Myasthenia gravis
- Megacolon
- Obstructive uropathy
- Tachyarrhythmias
Relative caution:
- Prostatic hypertrophy
- Elderly patients (increased anticholinergic sensitivity)
Common Pitfall
The major clinical error is using hyoscine butylbromide as first-line therapy for biliary colic. The evidence clearly demonstrates that NSAIDs not only provide superior analgesia but also reduce the risk of progression to acute cholecystitis—a critical morbidity outcome 1. Hyoscine provides symptomatic relief only without disease-modifying effects.
Safety Profile
Hyoscine butylbromide is generally well-tolerated with mild, self-limiting anticholinergic effects 3:
- Dry mouth
- Blurred vision
- Urinary retention (rare)
- Tachycardia (uncommon)
No significant adverse events in clinical trials, particularly no CNS effects due to lack of blood-brain barrier penetration 6.
Clinical Algorithm
- First-line: Diclofenac 75 mg IM or indomethacin 100 mg (rectal if available)
- If NSAIDs contraindicated: Hyoscine butylbromide 20 mg IV/IM
- If pain persists: Consider opioid analgesia (though avoid morphine due to sphincter of Oddi spasm)
- Definitive management: Proceed with stone extraction per guidelines 7
Important Note on Drug Label Confusion
The FDA drug label provided 8 refers to buspirone (an anxiolytic), NOT hyoscine butylbromide (Buscopan). These are completely different medications. Buspirone has no role in biliary colic management.